Log in to search using one of your social media accounts:

 

TP53 and IDH2 somatic mutations are associated with inferior overall survival following allogeneic hematopoietic cell transplantation for myelodysplastic syndrome

This study furthers implementation of clinical genomics in MDS and identifies TP53 and IDH2 as targets for pre- or post-transplant therapy.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionsThe burden of tAML/tMDS in Victoria is likely to be underestimated. Linkage between VCR and clinical registries is needed to provide more accurate insights.
Source: Internal Medicine Journal - Category: Internal Medicine Authors: Tags: Original Article Source Type: research
Conclusion Bendamustine is an effective therapy with limited long-term sequelae in patients with lymphoid malignancies. Micro-Abstract Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. To determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
MDS, or myelodysplastic syndrome, refers to a group of blood cancers. In this article, learn about the symptoms and complications of this disease.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Are the myeloid malignancies leading the way, based on our ability to easily obtain tumor tissue and success in CML, or are they following, given the use of multi-gene panels to treat upfront advanced lung cancer and the remarkable outcomes using check point inhibitors to treat formerly intractable solid tumors? Past achievements in the leukemias have been impressive but incomplete. In chronic phase CML we have essentially curative treatments; in myeloproliferative neoplasms we know the mutations but possess only partially effective therapies; and in myelodysplastic syndrome many mutations have been described but effective...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Uncontrolled dyspnea is terrifying for patients and has a negative effect on quality of life (QOL) (Gupta, Lis,&Grutsch, 2007). Fatigue (92%), dyspnea (63%), and pain (55%) have been reported as the three most prevalent symptoms for patients diagnosed with higher risk myelodysplastic syndromes (MDS) (Efficace et al., 2015). Dyspnea and associated symptoms in advanced cancer are not adequately treated due to limited research and understanding of the experience (Twaddle et al., 2007).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Cancer survivors may develop a second cancer as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) and this has been an emerging problem for acute promyelocytic leukemia (APL) patients in complete remission (CR).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Publication date: July 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement Author(s): Umang Patel, Rajyalakshmi Luthra, L. Jeffrey Medeiros, Keyur P. Patel The classification and risk stratification of myeloid neoplasms, including acute myeloid leukemia, myelodysplastic syndromes, myelodysplastic syndromes/myeloproliferative neoplasms, and myeloproliferative neoplasms, have increasingly been guided by molecular genetic abnormalities. Gene expression analysis and next-generation sequencing have led to the ever increasing discovery of somatic gene mutations in myeloid neoplasms. Mutations have been ide...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion The study participants treated with inpatient, induction chemotherapy experienced statistically significant improvement in their quality of life at 1 month. The outpatient, nonintensive study participants had stable quality of life at 1 month. Micro-Abstract The results of the present pilot study can be used to counsel older patients with acute myeloid leukemia and high-risk myelodysplastic syndrome regarding treatment choices that will align with their goals for their quality of life. Future studies are needed with a larger and more diverse patient sample to address whether the more intensive treatment approach...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion This study furthers implementation of clinical genomics in MDS and identifies TP53 and IDH2 as targets for pre- or post-transplant therapy. Micro-Abstract Allogeneic hematopoietic cell transplantation represents the only treatment option capable of offering a cure to patients with myelodysplastic syndrome. Here, we demonstrate that presence of mutations in TP53 and IDH2 in myelodysplastic syndrome confer a poor prognosis even in the setting of allogeneic transplantation.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Bendamustine is an effective therapy with limited long-term sequelae in patients with lymphoid malignancies. Teaser Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. In order to determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Study | Transplants